CA2904586A1 - Methods and compositions for the treatment and/or prevention of type 1 diabetes - Google Patents

Methods and compositions for the treatment and/or prevention of type 1 diabetes Download PDF

Info

Publication number
CA2904586A1
CA2904586A1 CA2904586A CA2904586A CA2904586A1 CA 2904586 A1 CA2904586 A1 CA 2904586A1 CA 2904586 A CA2904586 A CA 2904586A CA 2904586 A CA2904586 A CA 2904586A CA 2904586 A1 CA2904586 A1 CA 2904586A1
Authority
CA
Canada
Prior art keywords
cells
stem
progenitor cells
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2904586A
Other languages
English (en)
French (fr)
Inventor
Habib Zaghouani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri–St. Louis
Original Assignee
University of Missouri–St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri–St. Louis filed Critical University of Missouri–St. Louis
Publication of CA2904586A1 publication Critical patent/CA2904586A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2904586A 2013-03-08 2014-03-10 Methods and compositions for the treatment and/or prevention of type 1 diabetes Abandoned CA2904586A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775115P 2013-03-08 2013-03-08
US61/775,115 2013-03-08
PCT/US2014/022321 WO2014138725A1 (en) 2013-03-08 2014-03-10 Methods and compositions for the treatment and/or prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
CA2904586A1 true CA2904586A1 (en) 2014-09-12

Family

ID=51492039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904586A Abandoned CA2904586A1 (en) 2013-03-08 2014-03-10 Methods and compositions for the treatment and/or prevention of type 1 diabetes

Country Status (7)

Country Link
US (2) US11338036B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964750B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016510766A (cg-RX-API-DMAC10.html)
CN (1) CN105358678A (cg-RX-API-DMAC10.html)
AU (1) AU2014225307A1 (cg-RX-API-DMAC10.html)
CA (1) CA2904586A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014138725A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2018057825A1 (en) * 2016-09-23 2018-03-29 The Curators Of The University Of Missouri Antigen-specific immune modulation
JP2018141728A (ja) * 2017-02-28 2018-09-13 トヨタ自動車株式会社 生活習慣病の診断方法
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EP3873601A4 (en) * 2019-05-14 2022-03-23 Provention Bio, Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4481946A (en) 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4486188A (en) 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US7744876B2 (en) * 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
EP1668119A2 (en) * 2003-09-15 2006-06-14 Ramot at Tel Aviv University Ltd. Insulin-producing bone marrow derived cells and methods of generating and using same
JP4838724B2 (ja) * 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
US20120058105A1 (en) * 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications

Also Published As

Publication number Publication date
EP2964750A1 (en) 2016-01-13
JP2016510766A (ja) 2016-04-11
US20220008535A1 (en) 2022-01-13
WO2014138725A1 (en) 2014-09-12
EP2964750A4 (en) 2016-08-17
US11338036B2 (en) 2022-05-24
AU2014225307A1 (en) 2015-09-24
US20160015811A1 (en) 2016-01-21
CN105358678A (zh) 2016-02-24
EP2964750B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
US20220008535A1 (en) Methods and compositions for the treatment and/or prevention of type 1 diabetes
JP7561893B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用
JP6416855B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
JP6259763B2 (ja) Ｐｄ−ｌ１に基づく免疫療法
AU2014337385B2 (en) Chimeric antigen receptor T cell switches and uses thereof
KR102173938B1 (ko) 림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법
US20160376305A1 (en) Compositions containing hc-ha/ptx3 complexes and methods of use thereof
WO2013184976A2 (en) Compositions and methods for antigen-specific tolerance
EP3185885B1 (en) Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
KR20190126798A (ko) 당뇨병 치료를 위한 펩티드 및 방법
RS58343B1 (sr) Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
AU2004206842A1 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US20200353040A1 (en) Pharmaceutical Composition Comprising an APL Type Peptide
CN117279650A (zh) 细胞治疗方法
KR20250166298A (ko) 외인성 인슐린 사용을 감소시키는 방법
JP2021512905A (ja) 寛容化粒子によるセリアック病の治療
JP2024534926A (ja) 寛容性を誘導するための方法及び組成物
US20070041973A1 (en) Compositions and methods for treating, preventing and/or reversing type-1 diabetes
WO2022161484A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
WO2006052660A2 (en) Il-7 receptor blockade to suppress immunity
US12508285B2 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
CA3086280C (en) Pharmaceutical composition comprising an apl peptide
IL256199B1 (en) Multi-peptide composition
US20160361414A1 (en) Methods of Treating and Preventing Minor Histocompatibility Antigen-Mismatched Grafts
CN121941496A (zh) 下调和上调通路的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190308

FZDE Discontinued

Effective date: 20220310